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To investigate the safety and efficacy of subretinal injection of human Wharton’s Jelly-
derived mesenchymal stem cells (hWJ-MSCs) on retinal structure and function in Royal
College of Surgeons (RCS) rats.
Methods
RCS rats were divided into 2 groups: hWJ-MSCs treated group (n = 8) and placebo control
group (n = 8). In the treatment group, hWJ-MSCs from healthy donors were injected into the
subretinal space in one eye of each rat at day 21. Control group received saline injection of
the same volume. Additional 3 animals were injected with nanogold-labelled stem cells for
in vivo tracking of cells localisation using a micro-computed tomography (microCT). Retinal
function was assessed by electroretinography (ERG) 3 days before the injection and
repeated at days 15, 30 and 70 after the injection. Eyes were collected at day 70 for histol-
ogy, cellular and molecular studies.
Results
No retinal tumor formation was detected by histology during the study period. MicroCT
scans showed that hWJ-MSCs stayed localised in the eye with no systemic migration.
Transmission electron microscopy showed that nanogold-labelled cells were located within
the subretinal space. Histology showed preservation of the outer nuclear layer (ONL) in the
treated group but not in the control group. However, there were no significant differences in
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the ERG responses between the groups. Confocal microscopy showed evidence of hWJ-
MSCs expressing markers for photoreceptor, Müller cells and bipolar cells.
Conclusions
Subretinal injection of hWJ-MSCs delay the loss of the ONL in RCS rats. hWJ-MSCs
appears to be safe and has potential to differentiate into retinal-like cells. The potential of
this cell-based therapy for the treatment of retinal dystrophies warrants further studies.
Introduction
Inherited retinal degenerative diseases such as retinitis pigmentosa (RP) are the major cause of
irreversible blindness worldwide. Currently, there is no effective treatment either for prevent-
ing or slowing the progression of the disease. Genetic therapy had been challenging as there is a
wide range of genetic mutations involved and targeting every individual mutations is techni-
cally difficult. Cell based therapy seems to be a promising strategy in RP as it has the potential
to regenerate new photoreceptors or retinal pigment epithelial (RPE) cells. Several types of
stem cells had been investigated. However, in vivo studies showed that cells derived from
human umbilical cord tissue appears to be the most effective in rescuing photoreceptors and
retinal function [1].
Fetal stem cells are of different entities and can be obtained from two distinct sources,
namely the fetus proper (fetal bone marrow[2], lung[3],spleen, liver[4]and peripheral blood
[5]) and umbilical cord tissue (e.g umbilical cord blood[6], Wharton’s jelly, amniotic fluid[7],
placenta[8] and amnion[9]). Umbilical cord tissue itself harbours different stem cell population
in its many compartments namely amnion, subamnion, Wharton’s jelly, perivascular, adventi-
tia, endothelium and umbilical cord blood and the differences in stemness characteristics have
been reported[10,11].
Stem cells derived directly from uncontaminated Wharton’s jelly are less heterogenous and
possess unique beneficial properties over other mesenchymal stem cells[11–15]. HumanWhar-
ton’s Jelly-derived Mesenchymal Stem Cells (hWJ-MSCs) in its pure form have many advan-
tages over other type of stem cells including higher proliferation rates, stemness characteristics
that lasts several passages in vitro, wide multipotency, hypoimmunigenicity and anticancer
properties[12]. hWJ-MSCs evoked minimal immune reactivity with low expression of MHC I
molecules and no expression of MCH II molecules; rendering them a good source of allogeneic
cell transplantation[14,16]. hWJ-MSCs has greater differentiation potential [10,12,17] than
other tissues in umbilical cord. The potential of hWJ-MSCs to differentiate into neurons[17–
20] especially retinal progenitor cells[21] is a promising feature in cell therapy for conditions
such as retinal degeneration. Apart from that, hWJ-MSCs can also synthesize and secrete tro-
phic factors or cytokines and to support the expansion and function of other neural cells
[17,18,20,22]. Trophic factors secreted by hWJ-MSCs showed a better neural differentiation
and neural cell migration when compared with trophic factors by bone marrow-derived mes-
enchymal stem cells [23].
hWJ-MSCs has been studied widely in many conditions such as ischemic stroke[24], spinal
cord injury[25], Parkinson disease[26], cardiovascular disease[27,28], cartilage disease[29],
liver injury[30], skin healing[31]. However, the application of hWJ-MSCs in its pure form for
treating retinal degenerative diseases have not been studied previously. Thus, the purpose of
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this study was to investigate the safety and efficacy of subretinal injection of hWJ-MSCs on
preservation of the outer retinal structure and function in a rat model of retinal degeneration.
Methods
The study was approved by the Universiti Kebangsaan Malaysia Animal Ethnics Committee
(UKMAEC) (Approval number: PP/OPHTAL/2011/HASLINA) and all experiments were con-
ducted in accordance with the guidelines drawn by UKMAEC and also conformed to the
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Animals
Pigmented dystrophic Royal College of Surgeons (RCS) rats were obtained from the National
BioResource Project (NBRP) for the Rat in Japan (NBRP Rat no: 0011, Kyoto, Japan). RCS rats
have a causative gene rdy causing a deletion in the Mertk gene encoding the tyrosine kinases
receptor. This results in retinal abnormality starting at 3 weeks of age where RPE fails to phago-
cytose shed photoreceptor cells and subsequently leads to apoptosis of photoreceptors; mim-
icking human retinal degeneration[32,33]. Animals were housed in animal laboratory in
Universiti Kebangsaan Malaysia with a 12-hour light/dark cycle in individually ventilated
cages. The day of injection was considered as P0. All interventions were performed under full
anaesthesia with intramuscular injection of ketamine (80 mg/kg) and xylazine (7.5 mg/kg)
[34].
Cell preparation
In this study, we use a more defined mesenchymal stem cells that is derived from human
Wharton’s Jelly rather than the whole umbilical cord tissue. The cell source used is also cul-
tured using animal-free culture media that is important in developing a cell based therapy for
human use.
HumanWharton’s Jelly mesenchymal stem cells from a single donor were obtained from a
local stem cell bank (CryoCord Malaysia). Human umbilical cord was collected from the
donor at full-term gestation with the mother’s consent for research purpose. All the cell prepa-
ration were done in a cGMP accredited laboratory. Umbilical cord blood was drained before
cord tissue pieces were cut open lengthwise. The umbilical cord Wharton’s Jelly will be shred-
ded and then enzymatically digested using collagenase (Worthington Biochem, USA) for 1–2
hours at 37°C to facilitate detachment and loosening of the Wharton’s jelly into culture
medium. The mesenchymal cells were isolated fromWharton’s jelly by passing the tissue
through a syringe and needle. They were then cultured in Dulbecco’s modified Eagle’s medium
(DMEM)-low glucose (Gibco,USA)+10% human serum+100U/ml penicillin and 100μg/ml
streptomycin and 0.25μg/ml amphotericin (Gibco,USA). The culture-expanded cells were also
cryopreserved using standard cryopreservation protocol until being used in the following
research experiment.
Average cell viability upon thawing was 92.1%. The cells were then characterized with flow
cytometric analysis, gene expression with real-time polymerase chain reaction (PCR) and mul-
tilineage differentiation tests according to International Society for Cellular Therapy (ISCT)
criteria for mesenchymal stem cells[35]. Immunophenotyping with flow cytometric analysis
showed positive surface markers expression of CD90, CD105 and CD73. The cells were nega-
tive for hematopoietic markers of CD34 and CD45 as well as low expression for HLA-DR (S1
Fig). Real-time PCR showed expression of stemness genes relative to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) as a reference gene; namely Sox-2, Nanog 3, Nestin, BST-1,
OCT-4, FZD-9, FGF-4, Rex-1 and ABCG2 (S1 Table). Differentiation tests showed the ability
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of hWJ-MSCs to differentiate into all three lineages: adipogenic, osteogenic and chondrogenic
by staining positively for Oil Red O, Alizarin Red S and Alcian Blue respectively (S2 Fig). Apart
from that, hWJ-MSCs were also tested for differentiation into neurons. They were incubated in
α-MEM containing 1 mM b-mercaptoethanol (BME) without serum for 24 h. The culture
medium was then replaced with differentiation medium consisting of α-MEM containing 10%
FBS and 35 ng/ml all-trans-retinoic acid (ATRA). Three days later, cells were finally trans-
ferred to α-MEM containing 10% FBS and trophic factors (5 mM forskolin, 10 ng/ml recombi-
nant human basic fibroblast growth factor (bFGF), 5 ng/ml platelet- derived growth factor-AA
(PDGF-AA) and 200 ng/ml heregulin-b1-EGF-domain and cultured for an additional 8 days
before they were ready for in vitro evaluation. Both the induced cells and non-induced cells
were then counterstained with glial fibrillary acidic protein (GFAP) and nestin and viewed
with confocal microscopy. hWJ-MSCs stained positive for both GFAP and nestin which are
markers for neurons (S3 Fig). Cells at passages 4 to 5 were used throughout this experiment.
Preparation of gold nanoparticles-loaded hWJ-MSCs
The quality of the gold nanoparticles used in this study was assessed by determining the opti-
mal absorption wavelength of the gold nanoparticles in different culture medium with a spec-
trophotometer. The best absorption wavelength was to enable reliable results when measuring
the concentration of gold nanoparticles. Following 24 hours incubation of gold nanoparticles
on hWJ-MSCs, the supernatants were harvested and the amount of gold nanoparticles in it
were diluted in water before being measured at optimal absorption wavelength. This is to mea-
sure the gold nanoparticles released by the cells (exocytosis). Gold nanoparticle (BBI Interna-
tionals) solutions were centrifuged and the pellet resuspended in phenol red free medium at a
concentration of 1x109 nanoparticles/ml. The hWJ-MSCs culture media was then removed
from the flasks and 200 μl/cm2 of nanogold particle medium (1x109 particles/ml) was then
added to the cell culture flask and left to be incubated for a day. The supernatant containing
nanogold particles were then removed after 24 hours. The nanogold-loaded hWJ-MSCs were
washed with phosphate-buffered saline.
Cell viability for hWJ-MSCs after gold nanoparticles loading was evaluated with LIVE/
DEAD staining. Stock solution of calcein AM and ethidium homodimer-III were diluted with
phosphate-buffered saline according to the manufacturer’s (Biotium.Inc, USA) recommenda-
tions to a concentration of 2μM and 4μM respectively. hWJ-MSCs growth medium was aspi-
rated from the wells and the cells were washed two to three times with phosphate-buffered
saline. Incubation of cells in the LIVE/DEAD stain was performed for 45 min at room tempera-
ture. They were then washed two to three times with phosphate-buffered saline. The stained
cells were then viewed with fluorescence microscopy (Leica DMI2000B microscope equipped
with a Leica DF290 camera) under 10x magnification. Controls are cells not loaded with gold
nanoparticles. Viability of cells was then evaluated at days 1, 5 and 10 which correlated to the
number of days after the gold nanoparticles loading.
Cell proliferation assay was done using CellTiter-Glo Luminescent Cell Assay (Promega,
USA). Briefly, CellTiter-Glo reagent was prepared according to the manufacturer’s recommen-
dations and added to cells at a concentration of 100 μl/mL of medium. The samples were incu-
bated according to the culture protocol. The plate and its contents were left at room
temperature for 30 min. An equivalent volume of CellTiter-Glo reagent to the volume of cell
culture medium in each well was added and mixed for few min on an orbital shaker to induce
cell lysis. The plate was then left to incubate at room temperature for 10 min to stabilise the
luminescent signal. The luminescence was then recorded with GloMax luminometer. Cells not
incubated with gold nanoparticles acted as controls. A blank sample with no cells was used and
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deducted from all measurements. Cytotoxicity was evaluated at day 1, day 5 and day 10. Tripli-
cate samples were used and the assay was repeated twice.
Electroretinography
Electroretinography was performed 3 days before the injection (day -3) and repeated at days
15, 30 and 70 post injection. We used the day of injection as reference day 0. Animals were
dark adapted overnight for at least 12 hours before being anesthetized with intramuscular
injection of ketamine (80 mg/kg) and xylazine (7.5 mg/kg). Topical anesthesia of tropicamide
0.5% and phenylephrine 2.5% were used to dilate the pupils. Body temperature was kept at
36°C with a warm blanket.
ERGs were recorded with a gold wire loop placed on cornea and good contact between cor-
nea and electrode was assured with a drop of saline. The reference gold-cup electrode was
placed in the mouth and the ground needle electrode was inserted to the tail. Preparation for
ERG recordings were conducted under dim red light.
All recordings were performed using an Espion system (Espion e2, Diagnosys LLC; USA).
An average of at least three consistent recordings was taken for each stimulus intensity. The
stimulus intensity ranged from -4.0 to 1.0 log cd.s/m2. In addition, a double flash recording
protocol presented at 1.0 cd.s/m2 with the inter-stimulus interval of 0.7s was performed to
obtain an isolated cone response.
Cell Injection
Cells were trypsinized, washed and suspended in balanced salt solution prior to injection. The
viability of cells were tested in vitro with trypan blue staining after passing through a 30G nee-
dle as cell lysis was a concern. At 30G, the cells showed a viability of 80–90%.
At the age of days 21–23, 8 RCS rats kept under xylazine-ketamine anaesthesia received a
trans-scleral subretinal injection of a suspension of hWJ-MSCs 2 μl (1x105 cells/μl) (S4 Fig).
The procedure was visualized with an operating microscope through a dilated pupil. The site of
injection was exposed using a traction suture on the conjunctiva (Figure A in S4 Fig). Conjunc-
tival periotomy was done at the injection site superotemporally (Figure B in S4 Fig) and a sub-
retinal injection of cells was done with a 30G Hamilton syringe (Figure C in S4 Fig) after a
scleral tunnel was created using an insulin needle. The site of injection was marked with a 10/0
nylon suture (Figure D in S4 Fig). Immediately after the injection, the fundus was examined to
check for complications and if present, the animal would be removed from the study.
All animals were given immunosuppression to reduce the risk of cell rejection. They were
given daily dexamethasone injections intraperitoneally (1.6 mg/kg, from the day of surgery) for
2 weeks. Cyclosporine-A (Bedford Labs, Bedford, MA) was added to their drinking water (210
mg/l; resulting in blood concentration of 250–300 μg/l from a day prior to injection to the
length of the entire experiment in order to reduce the risk of cell rejection. Eight RCS rats were
injected with hWJ-MSCs and another eight with balanced salt solution (BSS). Three rats were
injected with gold nanoparticles-loaded hWJ-MSCs.
Micro-computed tomography
Biodistribution of the stem cells after transplantation are important aspects to look into in
terms of safety profile cellular therapy. Apart from local distribution, we are also interested to
know whether the stem cells will home in or migrate to other parts of the body and their final
location. C.Villa had compared various modalities of in vivo tracking of stem cell by nanotech-
nologies ranging from magnetic resonance imaging, bioluminescence imaging to micro com-
puted imaging and found microCT to be a good method for in vivo tracking in murine animals
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[36,37]. MicroCT uses the all-embracing universal application of x-ray imaging method which
has high spatial resolution of distribution of nanoparticles labelled stem cells and reconstruc-
tion of 3D images. However, they used iron oxide nanoparticles in their study. Iron oxide had
been shown to be taken up by stem cells and undergone lysosome degradation which releases
free iron from the cytoplasm [38]which is toxic to the retina. Therefore, in this study, we
choose gold nanoparticles which is inert and has good optical properties. Furthermore, gold
had been used to track stem cell in renal study [39].
Micro-computed tomography were performed on 3 rats injected with gold nanoparticles-
loaded hWJ-MSCs using Skyscan 1076 at days 1, 30 and 70 post injection. The rats were anaes-
thesized and strapped to the holder. The source spot size was 8.88um at 45kVp (with 0.5 mm
Al filtering). We injected the rats with 2μl of gold loaded hWJ-MSCs at the gold nanoparticles
concentration of 1x109 particles/μl.
Histology
The rats were sacrificed at day 70 post injection for enucleation. Animals were euthanized with
sodium pentobarbital intravenously at a dose of 15mg/100g body weight and enucleation per-
formed. The enucleated eyes were immersed in 4% paraformaldehyde for an hour before
embedded in Optimal Cutting Temperature (OCT). The eyes were then cut in horizontal sec-
tions at 10μm thickness using cryostat and mount on glass slides. Hematoxylin and eosin stain-
ing were then performed. The outer nuclear layer (ONL) thickness at three different sites were
measured using QCapture Pro Software and averaged.
As for the electron microscopy, the eye cups were immediately fixed with 2.5% glutaralde-
hyde solution (pH 7.4) in 0.1M phosphate buffer for an hour and then treated with 1% osmium
tetroxide solution (OsO4) in 0.1M phosphate buffer for an hour. The eyes samples were then
dehydrated with graded ethanol and treated with epoxy propane and embedded in 812 resin.
The embedded retinas were sectioned serially for electron microscopy on an ultramicrotome
(Leica EM UC6, using a diamond knife. Semi-thick sections (500nm) were stained with 1%
Toluidine blue and viewed under microscope to confirm the site of interest. The ultra-thin
(76nm) series of sections were collected on a slot grid, stained with uranyl acetate and lead cit-
rate, and washed. The grids were viewed and serial sections were photographed under a Tecnai
G2 Spirit Biotwin (FEI Company, USA). The area of the retina distant from the graft was used
as a matching negative control for each eye.
Immunohistology Staining
The frozen sections of tissues were used for immunohistological staining. The tissues were cut
at 10μm thick and fixed in 4% paraformaldehyde. The slides were thawed at room temperature
for 30 min and tissue sections rehydrated with PBS for 15 min. The section were permeabilized
with PBS containing 0.2% Triton X-100 (PBST) for 20 min at room temperature. Non-specific
binding sites were blocked with 0.2% bovine serum albumin (BSA) (Zenon Mouse IgG Label-
ling Kit) and 5% of heat inactivated normal goat serum for 30 minutes. The sections were then
prepared with Zenon’s labelling complex according to the manufacturer’s recommendation.
(Molecular Probes Invitrogen Detection Technologies, 2008) The tissues were then counter-
stained with primary mouse monoclonal antibody-STEM121 (StemCells Inc, USA) specific for
human cytoplasmic marker to highlight the hWJ-MSCs, anti-rhodopsin antibody for rod pho-
toreceptors, anti-protein kinase C (PKC-α) antibody for bipolar cells, anti-glial fibrillary acidic
protein (GFAP) antibody for Muller glial cells, anti-cone arrestin antibody for cone photore-
ceptors, anti-recoverin antibody for cone bipolar, anti-microphthalmia-inducing transcription
factor (MITF) antibody for RPE specific markers and anti-ß-tubulin III antibody for immature
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neurons (all from Santa Cruz Biotech Inc, Europe). Except for STEM 121, all other antibodies
stained both human and rat proteins. The confocal images were viewed with Leica Application
Suite Advanced Fluorescence (LAS-AF) system.
Statistical Analysis
Data were presented as mean ± standard error of the mean. Mann-Whitney U test was used for
comparison of cell proliferation and ERG responses. Student’s t-test was used for comparison
of ONL thickness. Significance level was designated as p 0.05.
Results
Outer Nuclear Layer (ONL) Thickness
A representative histology at day 0 and day 70 of different experimental groups are shown in
Fig 1. The ONL (marked with asterisk) was clearly visible in the hWJ-MSCs injected eyes (with
approximately 10 cell thickness) but undetectable in the BSS injected eyes nor control eyes.
The ONL of the contralateral eye of the hWJ-MSCs injected animals was also undetectable
(Fig 1C). The average thickness of the ONL of the hWJ-MSCs injected eyes (24.55 ± 0.79 μm)
was significantly greater than that of the uninjected contralateral fellow eyes (3.94 ± 0.42 μm,
p<0.001) and eyes injected with BSS (4.65 ± 0.73 μm, p<0.001) (Fig 2).
In the hWJ-MSCs injected eyes, there was a generalised preservation of the outer nuclear
layer over the entire retina. The ONL at the site of injection (Fig 3A), middle region (Fig 3B)
and at the site furthest away from the site of injection (Fig 3C) are shown in Fig 3. The site of
injection was evident by a small remnant subretinal bump. The histology analysis did not show
any tumor formation or destruction of laminar structure after cell injection.
The engraftment and survival of hWJ-MSCs were determined by staining the sectioned reti-
nas of the RCS rats with Stem121 at day 70. Stem 121 is a pan human-specific antibody that
recognizes only human cytoplasmic protein marker. At day 70, hWJ-MSCs appeared to have
survived and migrated progressively to form a continuous layer of cells in the subretinal space
around the injected area (staining positive for stem121).
The retina sections expressed both stem 121 and various antibody markers namely rod rho-
dopsin, protein kinase (PKC-α), glial fibrillary acidic protein-GFAP, cone arrestin, recoverin,
microphthalmia-inducing transcription factor (MITF) and ß-tubulin III. These antibody
markers stained for both the rat and human cells. At day 70, positive staining of the antibody
markers (Fig 4) was detected in eyes injected with hWJ-MSCs but not in the control eyes, sug-
gesting that the injected hWJ-MSCs started to show characteristics of the various retinal neural
cells. There was also co-localizations of Stem 121 and photoreceptor markers (Fig 5) indicating
that hWJ-MSCs has the potential to differentiate into retinal neural cells.
Retinal Function
The dark adapted ERG a- and b-wave response amplitudes at 10 cd.s/m2 and the isolated cone
responses at days -3, 15 and 30 for each experimental group are shown in Fig 6. Although there
was a trend that the ERG amplitude of the injected group was greater than that of the non-
injected and control groups at days 15 and 30, the differences in ERG responses between the
studied groups were not statistically significant at any time point post injection. All groups
showed undetectable ERG at day 70.
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hWJ-MSCs Migration
The subretinal location of hWJ-MSCs was verified with injection of gold-loaded hWJ-MSCs
and localised using transmission electron microscopy (TEM) 5 days after the subretinal injec-
tion. TEM showed the subretinal localisation of gold-loaded hWJ-MSCs. Some of the gold
nanoparticles were seen being phagocytosed by the retinal pigment epithelium layer and
retained there (Fig 7). The hWJ-MSCs were also labelled with PKH 26 to determine the loca-
tion after the injection and confocal microscopy at 2 weeks showed the subretinal location of
the injected cells (Fig 8).
Non-invasive longitudinal study were then done in these rats with micro-computed tomog-
raphy scanning without sacrificing them for better understanding of the biodistribution of
hWJ-MSCs after engraftment in rat. Micro-computed tomography was done at day 1,day 30
and day 70 and showed localisation of the gold-loaded hWJ-MSCs to the engrafted eye (Fig
8A, 8B and 8C) (S1 Video, S2 Video and S3 Video) and no migration systemically were seen in
whole body scanning. This helps to establish the safety profile of the cell therapy as localised
effect is wanted and not for it to migrate systemically.
Fig 1. Histology of experimental groups. A representative histology at day 0 (A) and day 70 (B-E) of different experimental groups. At day 70, the ONL
were clearly detectable in eyes treated with hWJ-MSCs (B) compared to a thin layer or almost absent ONL in contralateral non-injected eye (C). The ONL
was undetectable in the BBS injected eye (D) or the follow control eye (E). RGC: retinal ganglion cell, IPL: inner plexiform layer, INL: inner nuclear layer
(indicated by double-headed arrows), ONL: outer nuclear layer (indicated by asterisks), RPE: retinal pigment epithelium. Scale bar represents 20μm.
doi:10.1371/journal.pone.0128973.g001
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Gold Nanoparticles
Nanoparticles of size 80 nm were used in this study. When dissolved in water, the different
concentrations of gold in water showed peak absorbance at 545 nm in UV-Vis spectra which is
the same as bare gold when dissolved in citrate solution (S5 Fig). The results showed that there
was no shift in optimal absorption wavelength for gold nanoparticles in different solutions. At
optimal absorption wavelength of 545 nm, the different concentrations of gold nanoparticles
showed a regression (R2) of 0.99 (Fig 9B). This showed the absence of gold nanoparticles in the
supernatant indicating that the exocytosed nanoparticles could be taken up again by the cell or
by its neighbouring cells.
After loading hWJ-MSCs with various concentration of gold nanoparticles, viability
remained good for all gold nanoparticles concentrations over a 10-day period with minimal
cell death. Fig 9A showed that most cells were live cells (labelled green) compared to the very
scant dead cells (labelled red marked by white arrows) in the LIVE/DEAD assay.
The proliferation profile of hWJ-MSCs with various concentration of gold nanoparticles are
shown in Fig 9C At day 1, there was no significant difference in cell count between control
sample and samples from any of the gold nanoparticle concentrations. At day 5, the cell count
was significantly reduced in the samples incubated with gold nanoparticle concentration of
1x1010 particles/ml or higher compared to the control sample. The cell count of the samples
incubated with gold nanoparticles was also significantly reduced at day 10 compared to the
Fig 2. Outer Nuclear Layer Thickness. The average ONL thickness of the hWJ-MSCs and BBS injected group at day 70 post injection. The ONL thickness
of the hWJ-MSCs injected eyes was significantly greater than that of the uninjected fellow eyes (p<0.001) and eyes injected with BSS (p<0.001). Error bars
indicate standard error of the mean.
doi:10.1371/journal.pone.0128973.g002
hWJ-MSCs in Retinal Degeneration
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control, but only at the concentration of 1x1011 particles/ml (p = 0.014). Thus, gold nanoparti-
cles concentration of 1x109 particles /ml was used in the in vivo experiment of this study.
Discussion
In this study, we demonstrate the safety and efficacy of subretinal injection of hWJ-MSCs in
delaying retinal degeneration in RCS rats. With regard to the safety, the hWJ-MSCs was local-
ised mainly within the eye, and there was no evidence of systemic distribution as demonstrated
by the microCT. There was also no tumorigenesis detected on histology study. In relation to
the efficacy, there were a significant preservation of outer nuclear layer in rats injected with
hWJ-MSCs compared to control at day 70. However, no significant improvement in retinal
function was observed in the treated group. The transplanted hWJ-MSCs expressed protein
markers for a number of antibodies, representing different components in the retina at day 70.
The underlying mechanisms of actions are possibly multifactorial. The co-expression of
both human STEM 121 and retinal cell markers in this study suggests that the hWJ-MSCs have
potential to differentiate into retinal-like cells in vivo. This is supported by the successful in-
vitro induction of hWJ-MSCs in this study to cells exhibiting neuronal markers. Apart from
that, other studies had also reported successful in vitro induction of hWJ-MSCs into neurons
and glia[18] and also retinal progenitor cells[21] indicating the potential of hWJ-MSCs in dif-
ferentiating into different cell lineages including cells that constitute the retinal layer.
However, the stimulus for in vivo differentiation in is still unclear. The diseased microenvi-
ronment in which hWJ-MSCs were in or the secretion of neurotrophic factors by hWJ-MSCs
creating an inducive microenvironment could have induced cellular differentiation. It is still
unknown at the moment and further studies are needed.
Apart from retinal differentiation, another hypothesis towards cellular rescue is the neuro-
protective effects by secretion of trophic factors by hWJ-MSCs. These cells had been shown to
secrete a number of diffusible neurotrophic factors in vitro which include interleukin 6 (IL-6),
Fig 3. Retinal histology of the injection and non-injection sites at day 70. In eye injected with hWJ-MSCs, there was a generalised preservation of outer
nuclear layer (double-headed arrows) over the whole retina as shown at the site of injection (A), middle region (B) and at the site furthest away from the site of
injection (C) at day 70. The site of injection was evident by a small remnant subretinal bump (red arrow). This showed that the preservation of outer nuclear
layer is not limited to the injection site. Scale bar represents 50 μm.
doi:10.1371/journal.pone.0128973.g003
Fig 4. Immunohistochemistry of the injected eyes and control at day 70. Confocal microscopy at day 70
of the hWJ-MSCs and saline injected eye. Positive staining of the retinal antibody markers was detected in
the hWJ-MSCs injected eyes but not in the saline injected eye. The antibodies used were Stem 121(green)
for mesenchymal stem cells, Rhodopsin (red) for rod photoreceptors, MITF (green) for RPE specific markers,
β tubulin (green) for immature neurons, anti-cone arrestin (red) for cone photoreceptors, PKC-α (red) for
bipolar cells and recoverin (red) for cone bipolar. All slides were counterstained with DAPI (blue) to label the
nucleus. Scale bar (white) represents 1000 μm.
doi:10.1371/journal.pone.0128973.g004
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brain derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), neuro-
trophin 3(NTF3) and fibroblast growth factor (FGF-2)[16,40]. Trophic factors secreted by
hWJ-MSCs also showed better neuronal differentiation and neural protection compared with
bone marrow derived mesenchymal stem cells [23]. Despite the lack of migration of
Fig 5. Confocal microscopy of the whole eye injected with hWJ-MSCs. Confocal microscopy of the whole eye (A) and magnified images of the injected
site (B-D). Red box represents the magnified area and the white arrow indicates the injection site. Co-localisation of DAPI (blue) and stem 121 (red) with
rhodopsin (green), GFAP (green) and PKC-α (green) was detected at day 70 post injection, indicating that hWJ-MSCs has the potential to differentiate to
retinal neuronal cells. Scale bar represents 10 μm.
doi:10.1371/journal.pone.0128973.g005
hWJ-MSCs in Retinal Degeneration
PLOS ONE | DOI:10.1371/journal.pone.0128973 June 24, 2015 12 / 20
hWJ-MSCs to cover the entire retina as shown by the micro-computed tomography, it is still
able to maintain the preservation of ONL on the opposite side of the retina. This suggests that
neuroprotection by the secretion of trophic factors is the most plausible answer. The role of
secretome of hWJ-MSCs in retinal regeneration should be studied further in future research
and unfortunately, it is one of our limitation of the study at the moment.
The third mechanism of rescue could be by cell fusion where the hWJ-MSCs fuse with the
rat cells and adopt the phenotype of the diseased cells, therefore, mediating repair and rescue.
Oxidative damage and cell-to-cell contact were postulated to be a prerequisite to stimulate
fusion [41]. In our study, the expression of both human and rat markers as shown by the con-
focal microscopy could be explained by fusion mechanism. The hWJ-MSCs may have fused
with the adjacent sick cells and rescue them. Further studies are needed to demonstrate this
hypothesis further.
Several factors could contribute to the poor functional results observed in this study. Firstly,
the dose of the injection of hWJ-MSCs could be inadequate. An escalating dose could be tested
in the future to look for the correct dosage needed for functional efficacy. Multiple injections at
different site could also be an option to reach the desired efficacy and achieve a greater area of
Fig 6. Retinal function. The dark adapted ERG a- and b-wave response amplitudes (10 cd.s/m2) and the isolated cone response at days -3, 15 and 30 for
each experimental group. Although there was a trend that the ERG amplitude of the injected group was higher than that of the non-injected and control
groups at days 15 and 30, the differences in ERG responses between the studied groups were not statistically significant at any time point post injection
(p>0.05). All groups showed undetectable ERG at days 70. Error bars indicate standard error of the mean.
doi:10.1371/journal.pone.0128973.g006
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preservation with multiple sites. Second, it is also possible that the changes in retinal function
was minimal and the full-field system is not sensitive enough to detect this changes. A focal or
multifocal ERG system would be more sensitive to detect a small or localised functional
changes at the injection site.
Another possible explanation is whether the differentiated retinal neuron cells are func-
tional; whether there are synaptic contacts or integration with the remaining retinal cells. The
formation of synaptic contacts or integration may take a longer time to establish; more than 70
days post injection of the study period and hence, rescue or restoration of visual function may
be seen later. Synaptic markers such as synaptophysin could also be included in future confocal
studies. The sample size could also be too small to detect a significant difference.
As for the route of delivery, subretinal route of administration has the advantage of direct
implantation to the site of disease where the degenerating photoreceptors and RPE are targeted
and therefore yield better results. Intravitreal injection results in clusters intravitreally on the
lens posterior surface and also on the retinal surface [42]. The inner limiting membrane of the
retina poses a physical barrier preventing the migration of stem cells into the retina. On the
other hand, intravenous administration was not favoured due to few limitations. The blood ret-
inal barrier will limit the efficacy and the dose needed to reach therapeutic level may be high
apart from the potential effects of systemic exposure to hWJ-MSCs. Data on intravenous stem
cell delivery suggest that majority are trapped initially in the lungs[43] and can cause death by
pulmonary embolism in small laboratory animals[44]. Intravenous route requires chemoat-
tractant in order for the cells to home onto the site. There are no evidence to suggest that retini-
tis pigmentosa produces chemoattractant for the cells to reach retina. There was a study
showing the potential of MSCs in treating retinal degeneration by intravenous injection but
systemic distribution revealed deposition in other tissues including lungs, kidneys and liver
[45]. As MSCs have multipotent potentials, another cause of concern is the undesirable effect
of enhancing pre-existing tumour or relapses by cell fusion in systemic administration[46,47].
In developing a cell based therapy for retinal degeneration, the safety profile is another con-
cern. Unlike embryonic stem cell which is pluripotent and has unlimited proliferative capacity,
Fig 7. Transmission electronmicroscopy. Transmission electron microscopy demonstrated the uptake of gold nanoparticles (arrow heads) by the
hWJ-MSCs in vitro (A). At day 5 after injection into the cell, the gold nanoparticles laden cell was located in the subretinal space (B) and some of the gold
nanoparticles were seen taken up by the retinal pigment (arrow heads), (C) showed a magnified version of the gold laden cell in vivo.
doi:10.1371/journal.pone.0128973.g007
hWJ-MSCs in Retinal Degeneration
PLOS ONE | DOI:10.1371/journal.pone.0128973 June 24, 2015 14 / 20
hWJ-MSCs has less tendency to form teratoma [48] and in this study, histology showed no
tumor formation or abnormal vascularisation after hWJ-MSCs injection. The hWJ-MSCs also
stayed localised to the transplanted area in the eye and did not migrate systemically as shown
in the micro-computed tomography.
However, another possible explanation for the lack of migration shown by micro-computed
tomography could be limitation in the study by decreased gold nanoparticles loading over time
Fig 8. Tracking with micro-computed tomography.MicroCT images showing localisation of gold-loaded hWJ-MSCs in the right eye (A) at day 1 and it
remained in the eye with no further migration systemically at day 30 (B) and day 70 (C) post injection. PKH 26 (labelled red) showed the subretinal location of
hWJ-MSCs after the injection at week 2.
doi:10.1371/journal.pone.0128973.g008
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due to cell division and other mechanism such as exocytosis; the cell division could cover the
entire retina but the signals were too weak to be picked up by micro-computed tomography as
they undergone mitosis.
hWJ-MSCs has its attractiveness for a cell based therapy for retinal degeneration. Its advan-
tages include being an ethical cell source, having good proliferative rate, easily available, and
has low immunogenicity. Using it off-the-shelf rather than inducing it into differentiated cells
would not confine it to its limited capacity but instead allowing it to act through multiple
mechanisms as mentioned above with the plasticity to differentiate into different types of reti-
nal neurons rather than confined to a specific type of cell. Long tedious preparation of induc-
tion and differentiation may give rise to contamination and errors apart from the burden of
high cost consumption. In addition, hereditary conditions such as retinitis pigmentosa, have
underlying genetic abnormalities rendering autologous cells inappropriate for such treatment.
From this study, we can see that hWJ-MSCs has the potential as a cell therapy for retinal
degeneration. However, this preliminary study has its many limitations and need to be fol-
lowed up with further study for its many unaddressed issues. In this study, hWJ-MSCs demon-
strate the potential to integrate and differentiate into retinal cells; however synapse formation
needs to be established for visual function to be restored. Future directions can look into ribbon
Fig 9. Viability and cytotoxicity of hWJ-MSCs after gold nanoparticles loading. A) Representative LIVE/DEAD images of nanogold-loaded hWJ-MSCs
taken at day 1, day 5 and day 10 at different concentration showed good viability where most cells were live cells which were labelled green compared to the
very scant dead cells which were labelled red (indicated by white arrow). Scale bar 100μm. B) At optical density with the wavelength of 545 nm, different
concentrations of 80 nm gold nanoparticles dissolved in water showed a regression (R2) of 0.99. C) The proliferation profile of hWJ-MSCs with various
concentration of gold nanoparticles were evaluated over a 10-day period. Median values were represented by horizontal lines. Cell numbers on day 1, day 5
and day 10 are marked with blue circle, green square and pink triangle respectively. At day 1, there was no significant difference in cell count between control
sample and samples from any of the gold nanoparticle concentrations. At day 5, the cell count was significantly reduced in the samples incubated with gold
nanoparticle concentration of 1x1010 particles/ml or higher compared to the control sample (marked with asterisks). The cell count of the samples incubated
with gold nanoparticles was also significantly reduced at day 10 compared to the control, but only at the concentration of 1x1011 particles/ml (marked with
asterisks). (p = 0.014; Mann-Whitney U test).
doi:10.1371/journal.pone.0128973.g009
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synapses and function. Secretion of trophic factors in vivo and role of cell fusion are other
aspects that can be looked into.
In summary, subretinal injection of hWJ-MSCs delays the loss of the photoreceptors in RCS
rats. hWJ-MSCs appears to be safe and has potential to differentiate into retinal-like cells. The
potential of this cell-based therapy for the treatment of retinal dystrophies warrants further
studies.
Supporting Information
S1 Fig. Flow cytometric analysis. Immunophenotyping with flow cytometric analysis showed
positive surface markers expression of CD 73, CD90 and CD 105 and negative for hematopoi-
etic markers of CD 34 and CD 45 as well as reduced expression for HLA-DR.
(TIF)
S2 Fig. Differentiation ability of hWJ-MSCs into three different lineages. Adipogenic differ-
entiation of hWJ-MSCs with positive staining for oil red O (A), Chondrogenic differentiation
with positive staining for Alcian Blue (B) and Osteogenic differentiation with positive staining
for Alizarin Red S.
(TIF)
S3 Fig. Neuronal differentiation of hWJ-MSCs in vitro. Induced hWJ-MSCs showed positive
staining for both glial fibrillary acidic protein (GFAP) (A) and nestin (C) which are neuronal
markers compared to controls which were non-induced cells (B,D). Scale equals to 100μm.
(TIF)
S4 Fig. Injection technique (Figure A). The superotemporal sclera was exposed with traction
suture on conjunctiva (Figure B). Conjunctival periotomy was performed to expose the bare
sclera (Figure C). A sclera tunnel track was created with a 30G needle and cell injected with
Hamilton syringe. A bleb under the sclera was seen after the injection (Figure D). Site of injec-
tion marked with a suture.
(TIF)
S5 Fig. Optimal absorption wavelength of gold nanoparticles. Line graph showing different
concentrations of gold nanoparticles dissolved in water and bare gold in citrate solution exhib-
ited similar peak absorbance wavelength at 545nm in UV-Vis spectra and photo of 80nm cit-
rate-stabilized gold nanoparticles in water.
(TIF)
S1 Table. Gene expression for post-thaw hWJ-MSCs relative to GAPDH.
(TIF)
S1 Video. MicroCT 3D configuration of eye injected with gold-loaded hWJ-MSCs at day 1.
(MP4)
S2 Video. MicroCT 3D configuration of eye injected with gold-loaded hWJ-MSCs at day
30.
(MP4)
S3 Video. MicroCT 3D configuration of eye injected with gold-loaded hWJ-MSCs at day
70. 3D configuration with MicroCT showing localization of gold-loaded hWJ-MSCs to the site
of injection till day 70.
(MP4)
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